BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farooqi AA, Tabassum S, Ahmad A. MicroRNA-34a: A Versatile Regulator of Myriads of Targets in Different Cancers. Int J Mol Sci 2017;18:E2089. [PMID: 29036883 DOI: 10.3390/ijms18102089] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Grebenovsky N, Luma L, Müller P, Heckel A. Introducing LNAzo: More Rigidity for Improved Photocontrol of Oligonucleotide Hybridization. Chemistry 2019;25:12298-302. [PMID: 31386225 DOI: 10.1002/chem.201903240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Biersack B. Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma. Noncoding RNA Res 2018;3:213-25. [PMID: 30809600 DOI: 10.1016/j.ncrna.2018.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Zhang Y, Zhao D, Li S, Xiao M, Zhou H, Yang S, Hao Y, Dong S. Long non-coding RNA TUG1 knockdown hinders the tumorigenesis of multiple myeloma by regulating the microRNA-34a-5p/NOTCH1 signaling pathway. Open Life Sci 2020;15:284-95. [PMID: 33817217 DOI: 10.1515/biol-2020-0025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Zhao N, Wang G, Long S, Hu M, Gao J, Ran X, Wang J, Su Y, Wang T. MicroRNA-34a deficiency leads to impaired wound closure by augmented inflammation in mice. Ann Transl Med 2020;8:447. [PMID: 32395491 DOI: 10.21037/atm.2020.03.161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kalapanida D, Zagouri F, Gazouli M, Zografos E, Dimitrakakis C, Marinopoulos S, Giannos A, Sergentanis TN, Kastritis E, Terpos E, Dimopoulos MA. Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. Oncotarget 2018;9:36906-13. [PMID: 30651924 DOI: 10.18632/oncotarget.26385] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Emam MA, Khattab HI, Hegazy MG. Assessment of anticancer activity of Pulicaria undulata on hepatocellular carcinoma HepG2 cell line. Tumour Biol 2019;41:1010428319880080. [PMID: 31603389 DOI: 10.1177/1010428319880080] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
7 Liu H, Dong Y, Feng X, Li L, Jiao Y, Bai S, Feng Z, Yu H, Li X, Zhao Y. miR-34a promotes bone regeneration in irradiated bone defects by enhancing osteoblastic differentiation of mesenchymal stromal cells in rats. Stem Cell Res Ther 2019;10:180. [PMID: 31215466 DOI: 10.1186/s13287-019-1285-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
8 Jiang X, Chen W, Su H, Shen F, Xiao W, Sun W. Puerarin facilitates osteogenesis in steroid-induced necrosis of rabbit femoral head and osteogenesis of steroid-induced osteocytes via miR-34a upregulation. Cytokine 2021;143:155512. [PMID: 33824083 DOI: 10.1016/j.cyto.2021.155512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Weidle UH, Nopora A. Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models. Cancer Genomics Proteomics 2020;17:321-34. [PMID: 32576578 DOI: 10.21873/cgp.20192] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Naghizadeh S, Mohammadi A, Duijf PHG, Baradaran B, Safarzadeh E, Cho WC, Mansoori B. The role of miR-34 in cancer drug resistance. J Cell Physiol 2020;235:6424-40. [PMID: 32064620 DOI: 10.1002/jcp.29640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sharma P, Dando I, Strippoli R, Kumar S, Somoza A, Cordani M, Tafani M. Nanomaterials for Autophagy-Related miRNA-34a Delivery in Cancer Treatment. Front Pharmacol 2020;11:1141. [PMID: 32792960 DOI: 10.3389/fphar.2020.01141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Khan MB, Ruggieri R, Jamil E, Tran NL, Gonzalez C, Mugridge N, Gao S, MacDiarmid J, Brahmbhatt H, Sarkaria JN, Boockvar J, Symons M. Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma. Mol Med 2021;27:28. [PMID: 33765907 DOI: 10.1186/s10020-021-00293-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yang Z, Liu T, Ren X, Yang M, Tu C, Li Z. Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks. Cell Cycle 2022;:1-11. [PMID: 35699451 DOI: 10.1080/15384101.2022.2087755] [Reference Citation Analysis]
14 Najjary S, Mohammadzadeh R, Mansoori B, Vahidian F, Mohammadi A, Doustvandi MA, Khaze V, Hajiasgharzadeh K, Baradaran B. Combination therapy with miR-34a and doxorubicin synergistically induced apoptosis in T-cell acute lymphoblastic leukemia cell line. Med Oncol 2021;38:142. [PMID: 34655330 DOI: 10.1007/s12032-021-01578-8] [Reference Citation Analysis]
15 Ma S, Fu T, Zhao S, Gao M. MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. Eur J Pharmacol 2019;852:42-50. [PMID: 30851271 DOI: 10.1016/j.ejphar.2019.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
16 Mytsyk Y, Borys Y, Tumanovska L, Stroy D, Kucher A, Gazdikova K, Rodrigo L, Kruzliak P, Prosecky R, Urdzik P, Dosenko V. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma. Clin Exp Med 2019;19:515-24. [DOI: 10.1007/s10238-019-00574-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Asadi M, Talesh ST, Gjerstorff MF, Shanehbandi D, Baradaran B, Hashemzadeh S, Zafari V. Identification of miRNAs correlating with stage and progression of colorectal cancer. Colorectal Cancer 2019;8:CRC06. [DOI: 10.2217/crc-2018-0014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
18 Battaglia C, Venturin M, Sojic A, Jesuthasan N, Orro A, Spinelli R, Musicco M, De Bellis G, Adorni F. Candidate Genes and MiRNAs Linked to the Inverse Relationship Between Cancer and Alzheimer's Disease: Insights From Data Mining and Enrichment Analysis. Front Genet 2019;10:846. [PMID: 31608105 DOI: 10.3389/fgene.2019.00846] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Berentsen B, Patil S, Rønnestad K, Goff KM, Pajak M, Simpson TI, Wibrand K, Bramham CR. MicroRNA-34a Acutely Regulates Synaptic Efficacy in the Adult Dentate Gyrus In Vivo. Mol Neurobiol 2020;57:1432-45. [PMID: 31754996 DOI: 10.1007/s12035-019-01816-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Wang C, Jia Q, Guo X, Li K, Chen W, Shen Q, Xu C, Fu Y. microRNA-34 Family: From Mechanism to Potential Applications. The International Journal of Biochemistry & Cell Biology 2022. [DOI: 10.1016/j.biocel.2022.106168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ayers D. Noncoding RNAs and their epitranscriptomic influences in cancer. Epigenomics 2018;10:1361-3. [PMID: 30322271 DOI: 10.2217/epi-2018-0119] [Reference Citation Analysis]
22 Ahmad A. Epigenetic regulation of immunosuppressive tumor-associated macrophages through dysregulated microRNAs. Semin Cell Dev Biol 2021:S1084-9521(21)00236-6. [PMID: 34556420 DOI: 10.1016/j.semcdb.2021.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Konstatinell A, Coucheron DH, Sveinbjørnsson B, Moens U. MicroRNAs as Potential Biomarkers in Merkel Cell Carcinoma. Int J Mol Sci 2018;19:E1873. [PMID: 29949882 DOI: 10.3390/ijms19071873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
24 Ryu J, Ahn Y, Kook H, Kim YK. The roles of non-coding RNAs in vascular calcification and opportunities as therapeutic targets. Pharmacol Ther 2021;218:107675. [PMID: 32910935 DOI: 10.1016/j.pharmthera.2020.107675] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
25 Torossian A, Broin N, Frentzel J, Daugrois C, Gandarillas S, Saati TA, Lamant L, Brousset P, Giuriato S, Espinos E. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. Haematologica 2019;104:1428-39. [PMID: 30679328 DOI: 10.3324/haematol.2017.181966] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
26 Li Y, Li C, Li D, Yang L, Jin J, Zhang B. lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway. Onco Targets Ther. 2019;12:2649-2660. [PMID: 31040703 DOI: 10.2147/ott.s188054] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 13.3] [Reference Citation Analysis]
27 Huang J. Current developments of targeting the p53 signaling pathway for cancer treatment. Pharmacol Ther 2021;220:107720. [PMID: 33130194 DOI: 10.1016/j.pharmthera.2020.107720] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
28 Nie D, Fu J, Chen H, Cheng J, Fu J. Roles of MicroRNA-34a in Epithelial to Mesenchymal Transition, Competing Endogenous RNA Sponging and Its Therapeutic Potential. Int J Mol Sci 2019;20:E861. [PMID: 30781524 DOI: 10.3390/ijms20040861] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
29 Cavallari I, Grassi A, Del Bianco P, Aceti A, Zaborra C, Sharova E, Bertazzolo I, D'Agostino DM, Iafrate M, Ciminale V. Prognostic Stratification of Bladder Cancer Patients with a MicroRNA-based Approach. Cancers (Basel) 2020;12:E3133. [PMID: 33114775 DOI: 10.3390/cancers12113133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Kawami M, Takenaka S, Akai M, Yumoto R, Takano M. Characterization of miR-34a-Induced Epithelial-Mesenchymal Transition in Non-Small Lung Cancer Cells Focusing on p53. Biomolecules 2021;11:1853. [PMID: 34944497 DOI: 10.3390/biom11121853] [Reference Citation Analysis]
31 Miranda Furtado CL, Dos Santos Luciano MC, Silva Santos RD, Furtado GP, Moraes MO, Pessoa C. Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics 2019;14:1164-76. [PMID: 31282279 DOI: 10.1080/15592294.2019.1640546] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
32 Ji G, Zhou W, Li X, Du J, Li X, Hao H. Melatonin inhibits proliferation and viability and promotes apoptosis in colorectal cancer cells via upregulation of the microRNA-34a/449a cluster. Mol Med Rep 2021;23:187. [PMID: 33398374 DOI: 10.3892/mmr.2021.11826] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Su G, Sun G, Liu H, Shu L, Liang Z. Downregulation of miR-34a promotes endothelial cell growth and suppresses apoptosis in atherosclerosis by regulating Bcl-2. Heart Vessels 2018;33:1185-94. [PMID: 29704100 DOI: 10.1007/s00380-018-1169-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]